Kidney Transplantation Under FK 506

Thomas E. Starzl, John Fung, Mark Jordan, Ron Shapiro, Andreas Tzakis, Jerry McCauley, James Johnston, Yuichi Iwaki, Ashok Jain, Mario Alessiani, Satoru Todo

Research output: Contribution to journalArticlepeer-review

199 Scopus citations


The experimental immunosuppressive drug FK 506 was given to 36 renal transplant recipients, many of whom were highly sensitized. Ten were undergoing kidney retransplantation, 10 also underwent liver transplantation at an earlier time (6 patients) or concomitantly (4 patients), and 2 patients received a third organ (heart or pancreas) in addition to a liver and kidney. With follow-ups of 4 to 13 months, all but 2 of the 36 patients are alive, 29 (81%) are dialysis free, and most have good renal function. Twenty of the 29 dialysis-free patients are receiving no or low-dose (2.5 to 5.0 mg/d) prednisone therapy. Only one kidney was lost to cellular rejection. However, patients who had antidonor cytotoxic antibodies in current or historical serum samples had a high rate (3 of 9) of irreversible humoral rejection. A low incidence of posttransplant hypertension was noteworthy. Hirsutism and gingival hyperplasia were not observed. Serum cholesterol levels in patients who took FK 506 were unexpectedly low, and the effect on the level of uric acid was minimal. The side effects of FK 506 therapy include nephrotoxicity, neurotoxicity, and potential induction of a diabetic state. These are similar to the side effects of cyclosporine use, but probably less severe. The seeming safety, efficacy, and relative freedom from side effects of FK 506 encourage further trials in kidney transplantation.

Original languageEnglish (US)
Pages (from-to)63-67
Number of pages5
JournalJAMA: The Journal of the American Medical Association
Issue number1
StatePublished - Jul 4 1990

All Science Journal Classification (ASJC) codes

  • Medicine(all)


Dive into the research topics of 'Kidney Transplantation Under FK 506'. Together they form a unique fingerprint.

Cite this